Abstract
Tricyclic antidepressants are a widely used method of treatment in patients with neuropathic pain and fibromyalgia. They achieve their effect by virtue of their effect on the descending serotinergic inhibitory pathways. New evidence suggests that as well as these conventionally accepted inhibitory pathways that descending bulbospinal facilitatory pathways also exist and that the potential for agents that augment the serotinergic systems to actually magnify, rather than diminish pain actually exists. The clinical implications of these findings are discussed along with suggestions as to how these descending facilitatory drives may be minimized.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Neuropathic Pain & Symptom Palliation
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
